Diabetes
Conference Coverage
Liraglutide ‘option’ for treating pediatric type 2 diabetes
BARCELONA – ELLIPSE trial shows clinicians aren’t limited to metformin and insulin for children with diabetes.
Conference Coverage
Smoking, inactivity most powerful post-MI lifestyle risk factors
PARIS –
Latest News
Panel releases guidelines for red meat, processed meat consumption
"This assessment may be excessively pessimistic; indeed, we hope that is the case," the panel said.
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
Conference Coverage
COMISAIR: CGM ‘makes the difference’ in type 1 diabetes
BARCELONA –
Conference Coverage
RISE analyses highlight further youth vs. adult T2D differences
BARCELONA – New data delve further into the differences in insulin sensitivity and glucose response in youth and adults with type 2 diabetes.
Conference Coverage
CONCLUDE data inconclusive on hypoglycemia risk for degludec vs. glargine
BARCELONA – The primary endpoint of the study was not met, thus differences between the long-acting insulins could not be confirmed.
Conference Coverage
Machine learning–derived risk score predicts heart failure risk in diabetes patients
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
Conference Coverage
Semaglutide beats canagliflozin as second-line therapy for type 2 diabetes
BARCELONA –
News from the FDA/CDC
FDA approves oral semaglutide for HbA1c management in type 2 diabetes
It is the first glucagonlike peptide–1 receptor agonist treatment in pill form for this condition.
Conference Coverage
First data VERIFY value of early combination therapy in type 2 diabetes
BARCELONA –